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Background: The RhoA/Rho kinase intracellular signaling pathway is activated by receptor agonists coupled to small G membrane proteins, growth 
factors or by cytokines. There is experimental evidence on the role of Rho kinase (ROCK) on pathological ventricular remodeling and ventricular 
dysfunction, but few data in patients with heart failure. Aim: to determine the ROCK activity in systolic heart failure patients (HF). 
Methods: Consecutive stable HF patients in sinus rhythm, NYHA Class II or III, with low eyection fraction (EF < 35%) and optimal medical 
treatment and a control group matched by age and gender were included. HF etiology was hypertension (n = 10), coronary heart disease (n = 3) and 
idiophathic dilated cardiomyopathy (n = 4). ROCK activity was determined in circulating leukocytes by measuring the levels of phosphorylated/total 
myosin light chain phosphatase 1 (MYPT1) by Western blot. EF, left ventricular mass index (LVMI) and atrial size were determined by transthoracic 
echocardiography.
Results: mean ± SEM 
Controls (n = 17) HF (n = 17) P
Age (years) / (% men) 54 ± 1.8 / 76 60 ± 3 /70 NS
BMI (Kg/m2) 25 ± 0.8 26 ± 0.8 NS
MAP (mmHg) 88 ± 1.2 91 ± 4.5 NS
EF (%) 68 ± 5 25 ± 4 < 0.01
Left atrial area (cm2) 18 ± 0.8 32 ± 2.3 < 0.01
LV end diastolic diameter (mm) 48 ± 0.8 62 ± 1.7 < 0.01
LV septum (mm) 8 ± 0.3 10 ± 0.5 < 0.01
LVMI (g/m2) 78 ± 3 160 ± 12 < 0.01
MYPT1 P/T 1.2 ± 0,2 77.2 ± 23 < 0.0001
Abbreviations: MAP = mean arterial pressure, BMI = body mass index, p/t = phosphorylated / total
A significant negative correlation between EF and ROCK activity was seen (Rho - 0.6 p < 0.001) in HF patients.
Conclusion: ROCK activity is markedly increased in patients with stable chronic HF despite optimal medical treatment and is associated 
with pathologic LV remodeling and systolic dysfunction. The mechanisms of ROCK activation and its role in the progression of HF need further 
investigation.
